Want to see MEDS full AI Analyst Report?
MEDS Stock Chart & Stats
$0.96
--
Market closed
$0.96
--
Day’s Range― - ―
52-Week Range$0.82 - $73.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)9.86M
Market Cap
$9.87M
Enterprise Value$38.31
Total Cash (Recent Filing)$2.46M
Total Debt (Recent Filing)$32.62M
Price to Earnings (P/E)―
Beta0.04
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,197,633
10 Day Avg. Volume28,248,103
30 Day Avg. Volume9,858,713
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.28
Price to Sales (P/S)1.22
P/FCF Ratio-2.61
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Liability Reduction And Litigation ResolutionThe settlement could materially improve the company’s capital structure by removing approximately $19 million of liabilities and ending associated legal claims. A cleaner balance sheet and reduced legal overhang may improve financial flexibility and allow management to focus resources on operating initiatives.
Acquisition Adds Certified Laboratory Capability And CashThe Helomics acquisition expands DataMeds’ operating asset base beyond its existing platform while adding certified laboratory infrastructure and cash resources. These capabilities can support service delivery, broaden commercial opportunities, and provide operational capital during the next several quarters.
Expansion Into Oncology Diagnostics And Treatment SupportMoving from GLP-1 side-effect and Long COVID management into oncology creates a broader healthcare offering anchored by laboratory and diagnostic services. Expansion across screening, profiling, and patient support could diversify revenue opportunities and strengthen the platform’s strategic relevance.
Bears Say
Severe Revenue Contraction And Deeply Negative ProfitabilityThe sharp decline in revenue and deeply negative margins indicate that the current business scale is not supporting its cost structure. Unless pricing, costs, or revenue volume improve materially, continued losses could weaken execution capacity and make durable profitability difficult to achieve.
Persistent Operating Cash BurnSustained cash consumption means the core business is not currently funding its own operations or investments. Continued negative operating and free cash flow increases dependence on external capital, which can constrain strategic flexibility and expose the company to financing pressure.
Negative Equity And High LeverageNegative equity provides a weak capital buffer for creditors and shareholders, while debt materially exceeds the company’s equity base. This combination increases refinancing and dilution risk, limits financial flexibility, and leaves less capacity to absorb continued operating losses.
DataMeds AI News
MEDS FAQ
What was DataMeds AI’s price range in the past 12 months?
DataMeds AI lowest stock price was $0.82 and its highest was $73.00 in the past 12 months.
What is DataMeds AI’s market cap?
DataMeds AI’s market cap is $9.87M.
When is DataMeds AI’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were DataMeds AI’s earnings last quarter?
Currently, no data Available
Is DataMeds AI overvalued?
According to Wall Street analysts DataMeds AI’s price is currently Overvalued.
Does DataMeds AI pay dividends?
DataMeds AI does not currently pay dividends.
What is DataMeds AI’s EPS estimate?
DataMeds AI’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does DataMeds AI have?
DataMeds AI has 3,197,633 shares outstanding.
What happened to DataMeds AI’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of DataMeds AI?
Currently, no hedge funds are holding shares in MEDS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DataMeds AI
DataMEDS AI is a Health IT company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units. The company incorporates its artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contacts platform PharmacyChain™ to optimize the prescription medicines reimbursement and dispensing journey.
Technical Analysis
Cencora
―
Henry Schein
―
McKesson
―
Accendra Health
―
Hong Kong Pharma Digital Technology Holdings Ltd.
―
Ownership Overview
16.89% Insiders
14.15% Mutual Funds
― Other Institutional Investors
68.68% Public Companies and
Individual Investors